Elevai Labs (ELAB) Competitors $2.35 -0.14 (-5.62%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELAB vs. PHIO, RNAZ, ADXN, CDIO, BTAI, CARM, PRTG, BCLI, OBSV, and IBIOShould you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Phio Pharmaceuticals (PHIO), TransCode Therapeutics (RNAZ), Addex Therapeutics (ADXN), Cardio Diagnostics (CDIO), BioXcel Therapeutics (BTAI), Carisma Therapeutics (CARM), Portage Biotech (PRTG), Brainstorm Cell Therapeutics (BCLI), ObsEva (OBSV), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Elevai Labs vs. Phio Pharmaceuticals TransCode Therapeutics Addex Therapeutics Cardio Diagnostics BioXcel Therapeutics Carisma Therapeutics Portage Biotech Brainstorm Cell Therapeutics ObsEva iBio Phio Pharmaceuticals (NASDAQ:PHIO) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk. Is PHIO or ELAB more profitable? Phio Pharmaceuticals has a net margin of 0.00% compared to Elevai Labs' net margin of -223.41%. Elevai Labs' return on equity of -124.93% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -134.57% -108.39% Elevai Labs -223.41%-124.93%-85.10% Does the MarketBeat Community prefer PHIO or ELAB? Phio Pharmaceuticals received 38 more outperform votes than Elevai Labs when rated by MarketBeat users. Likewise, 64.41% of users gave Phio Pharmaceuticals an outperform vote while only 0.00% of users gave Elevai Labs an outperform vote. CompanyUnderperformOutperformPhio PharmaceuticalsOutperform Votes3864.41% Underperform Votes2135.59% Elevai LabsOutperform VotesNo VotesUnderperform Votes1100.00% Do insiders and institutionals believe in PHIO or ELAB? 57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of Elevai Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, PHIO or ELAB? Phio Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500. Do analysts prefer PHIO or ELAB? Phio Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 120.99%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Elevai Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Elevai Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, PHIO or ELAB? Elevai Labs has higher revenue and earnings than Phio Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.17Elevai Labs$2.45M0.85-$4.30M-$433.87-0.01 Does the media prefer PHIO or ELAB? In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Elevai Labs' score of -0.43 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Phio Pharmaceuticals Positive Elevai Labs Neutral SummaryPhio Pharmaceuticals beats Elevai Labs on 10 of the 16 factors compared between the two stocks. Get Elevai Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricElevai LabsPharmaceutical IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$2.08M$6.51B$13.67B$8.44BDividend YieldN/A2.64%3.61%4.11%P/E Ratio-0.049.1521.9219.77Price / Sales0.85259.303.44119.10Price / CashN/A65.8513.3534.62Price / Book0.056.472.104.52Net Income-$4.30M$144.21M$959.43M$248.23M7 Day Performance-2.08%2.64%3.15%0.77%1 Month Performance-15.77%4.80%12.55%13.45%1 Year Performance-99.75%-2.52%-6.34%7.67% Elevai Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABElevai Labs0.4983 of 5 stars$2.35-5.6%N/A-99.7%$2.08M$2.45M-0.0418News CoverageAnalyst UpgradeGap DownPHIOPhio Pharmaceuticals2.948 of 5 stars$1.81+2.8%$4.00+121.0%-73.8%$8.41MN/A-0.1710RNAZTransCode Therapeutics2.2599 of 5 stars$0.36+4.5%$10.00+2,699.6%-100.0%$8.34MN/A0.009Positive NewsEarnings ReportADXNAddex Therapeutics1.6667 of 5 stars$7.77-4.1%$30.00+286.1%-5.6%$8.24M$556,045.00-22.8530Gap UpCDIOCardio Diagnostics2.5341 of 5 stars$0.16-15.0%$2.00+1,171.5%-79.4%$8.20M$34,890.000.001Earnings ReportHigh Trading VolumeBTAIBioXcel Therapeutics3.9476 of 5 stars$1.48-3.3%$42.60+2,778.4%-95.7%$8.12M$2.27M-0.0490CARMCarisma Therapeutics2.4785 of 5 stars$0.19+1.3%$1.93+897.4%-87.6%$8.07M$19.63M-0.1220Gap UpPRTGPortage Biotech0.2966 of 5 stars$7.61-7.0%N/A+61.1%$7.98MN/A-0.186Upcoming EarningsGap UpBCLIBrainstorm Cell Therapeutics3.9737 of 5 stars$1.22+3.4%$30.00+2,359.0%-87.3%$7.96MN/A-0.2540Earnings ReportAnalyst ForecastGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150IBIOiBio1.1676 of 5 stars$0.79+2.3%$4.30+443.3%-67.1%$7.82M$375,000.000.00100High Trading Volume Related Companies and Tools Related Companies PHIO Alternatives RNAZ Alternatives ADXN Alternatives CDIO Alternatives BTAI Alternatives CARM Alternatives PRTG Alternatives BCLI Alternatives OBSV Alternatives IBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELAB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevai Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELAB Stock Free ELAB Stock Alerts